CD274 and non-small cell lung carcinoma: There is no need to detect PD-L1 status in the second-line treatment using nivolumab and atezolizumab, while second-line therapy with pembrolizumab can be used in the combined treatment of patients with PD-L1 TPS ≥ 1%, and first-line monotherapy is approved for patients with advanced non-small cell lung cancer with PD-L1 TPS ≥ 50% (35).